文献速递中毒与环境急症消化、代谢与肾脏急症

美国监狱阿片使用障碍治疗药物可及性的相关因素

Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.
PubMed 文献 · JAMA Netw Open · 2024-09-03
一句话结论美国全国代表性调查显示,仅43.8%的监狱向至少部分人提供阿片使用障碍治疗药物,12.8%向所有阿片使用障碍者提供。

该研究为全国代表性横断面调查,2022年6月至2023年4月邀请2791所美国监狱,1028所参与(应答率36.8%),927所纳入分析,加权代表全国3157所监狱。结果显示,43.8%(95%CI 40.5%-47.1%)的监狱向至少部分人提供阿片使用障碍治疗药物(MOUD,即丁丙诺啡、美沙酮和纳曲酮),仅12.8%(95%CI 10.7%-14.9%)向所有阿片使用障碍者提供。县社会脆弱性较低(每增加1个百分位,校正OR=0.28,95%CI 0.19-0.40)和距最近提供MOUD机构平均距离较短(每增加1个标准差,校正OR=0.80,95%CI 0.72-0.88)的监狱更可能提供MOUD。作者认为,增加监狱及周边社区MOUD可及性的努力和政策可能与帮助更多人获得治疗相关。

要点

  • 全国加权后,43.8%(95%CI 40.5%-47.1%)的监狱向至少部分人提供MOUD,仅12.8%(95%CI 10.7%-14.9%)向所有阿片使用障碍者提供。
  • 县社会脆弱性每增加1个百分位,监狱提供MOUD的校正OR=0.28(95%CI 0.19-0.40),社会脆弱性越低越可能提供。
  • 距最近提供MOUD机构平均距离每增加1个标准差,校正OR=0.80(95%CI 0.72-0.88),距离越短越可能提供。
  • 加权后55.6%(95%CI 52.3%-59.0%)的监狱位于非都市县,59.7%(95%CI 56.5%-63.0%)使用 contracted 医疗服务。
  • 作者认为,增加监狱及周边社区MOUD可及性的努力和政策可能与帮助更多人获得治疗相关。

适用人群与场景

  • 美国全国监狱,纳入联邦名单中分层随机抽取的2791所监狱,邀请了解监狱物质使用障碍服务的 staff 完成调查。
  • 分析纳入927所监狱,加权后代表全国3157所监狱;多数位于非都市县(1756所,55.6%;95%CI 52.3%-59.0%),59.7%(95%CI 56.5%-63.0%)使用 contracted 医疗服务。

研究设计与关键结果

  • 研究类型:全国代表性横断面调查(survey study),2022年6月至2023年4月通过邮件、电话和互联网调查1028所监狱,应答率36.8%(1028/2791)。
  • 主要结局:43.8%(95%CI 40.5%-47.1%)的监狱向至少部分人提供MOUD(丁丙诺啡、美沙酮和纳曲酮),12.8%(95%CI 10.7%-14.9%)向所有阿片使用障碍者提供MOUD。
  • 县社会脆弱性每增加1个百分位,监狱提供MOUD的校正OR=0.28(95%CI 0.19-0.40);距最近提供MOUD机构平均距离每增加1个标准差,校正OR=0.80(95%CI 0.72-0.88)。
  • 社会脆弱性采用美国疾病控制与预防中心2020年社会脆弱性指数综合排名,基于16项社会因素对县进行排名。

证据类型、等级与局限

  • 证据类型:全国代表性横断面调查。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,增加监狱及周边社区MOUD可及性的努力和政策可能与帮助更多人获得治疗相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In 2023, more than 80 000 individuals died from an overdose involving opioids. With almost two-thirds of the US jail population experiencing a substance use disorder, jails present a key opportunity for providing lifesaving treatments, such as medications for opioid use disorder (MOUD).

OBJECTIVES: To examine the prevalence of MOUD in US jails and the association of jail- and county-level factors with MOUD prevalence using a national sample.

DESIGN, SETTING, AND PARTICIPANTS: This survey study used a nationally representative cross-sectional survey querying 1028 jails from June 2022 to April 2023 on their provision of substance use disorder treatment services. The survey was conducted via mail, phone, and the internet. County-level data were linked to survey data, and binary logistic regressions were conducted to assess the probability that a jail offered any treatment and MOUD. A stratified random sample of 2791 jails identified by federal lists of all jails in the US was invited to participate. Staff members knowledgeable about substance use disorder services available in the jail completed the survey.

EXPOSURES: US Census region, urbanicity, jail size, jail health care model (direct employees or contracted), county opioid overdose rate, county social vulnerability (measured using the Centers for Disease Control and Prevention 2020 Social Vulnerability Index summary ranking, which ranks counties based on 16 social factors), and access to treatment in the county were assessed.

MAIN OUTCOMES AND MEASURES: Availability of any type of substance use disorder treatment (eg, self-help meetings), availability of MOUD (ie, buprenorphine, methadone, and naltrexone) to at least some individuals, and availability of MOUD to any individual with an OUD were assessed.

RESULTS: Of 2791 invited jails, 1028 jails participated (36.8% response rate). After merging the sample with county data, 927 jails were included in analysis, representative of 3157 jails nationally after weighting; most were from nonmetropolitan counties (1756 jails [55.6%; 95% CI, 52.3%-59.0%]) and had contracted health care services (1886 jails [59.7%; 95% CI, 56.5%-63.0%]); fewer than half of these jails (1383 jails [43.8%; 95% CI, 40.5%-47.1%]) offered MOUD to at least some individuals, and 405 jails (12.8%; 95% CI, 10.7% to 14.9%) offered MOUD to anyone with an OUD. Jails located in counties with lower social vulnerability (adjusted odds ratio per 1-percentile increase = 0.28; 95% CI, 0.19-0.40) and shorter mean distances to the nearest facility providing MOUD (adjusted odds ratio per 1-SD increase, 0.80; 95% CI, 0.72-0.88) were more likely to offer MOUD.

CONCLUSIONS AND RELEVANCE: In this study, few jails indicated offering frontline treatments despite being well positioned to reach individuals with an OUD. These findings suggest that efforts and policies to increase MOUD availability in jails and the surrounding community may be associated with helping more individuals receive treatment.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Flanagan Balawajder E, Ducharme L, Taylor BG, et al. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024. PMID: 39316401. doi:10.1001/jamanetworkopen.2024.34704

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。